null
ChEBI ID: 49043
| Member | Definition | Role |
|---|---|---|
| beta-butyrolactone | beta-Butyrolactone | |
| marizomib | A salinosporamide in which the core (1R)-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione skeleton is substituted at positions 1, 4, and 5 by (1S)-cyclohex-2-en-1-yl(hydroxy)methyl, 2-chloroethyl, and methyl groups, respectively (the 1R,4R,5S diastereoisomer). A potent proteasome inhibitor, it has attracted interest for potential use in the treatment of various cancers. | salinosporamide A |
| orlistat | A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. | orlistat |
| vittatalactone | Vittatalactone |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (0.59) | 18.7374 |
| 1990's | 135 (8.85) | 18.2507 |
| 2000's | 692 (45.38) | 29.6817 |
| 2010's | 533 (34.95) | 24.3611 |
| 2020's | 156 (10.23) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 278 (17.41%) | 5.53% |
| Reviews | 364 (22.79%) | 6.00% |
| Case Studies | 70 (4.38%) | 4.05% |
| Observational | 1 (0.06%) | 0.25% |
| Other | 884 (55.35%) | 84.16% |